Wed, 30 Sep 2026 17:30:00 -0400 · 26 days ago Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
Fri, 04 Sep 2026 16:30:00 -0400 · 7 weeks ago Bright Minds Biosciences to Present at Upcoming Conferences
Fri, 31 Jul 2026 08:30:00 -0400 · 2 months ago Vistagen Appoints Douglas J. Williamson to its Board of Directors
Tue, 26 May 2026 19:18:00 -0400 · 5 months ago Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
2026-05-21T21:31:11.000Z · 5 months ago Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
2026-05-20T10:45:58.000Z · 5 months ago Bright Minds price target raised to $220 from $190 at Piper Sandler DRUG
2026-03-04T13:39:47.000Z · 7 months ago Bright Minds price target raised to $145 from $115 at H.C. Wainwright
Wed, 25 Feb 2026 16:30:00 -0500 · 8 months ago Bright Minds Biosciences to Present at Upcoming Conferences
Fri, 09 Jan 2026 11:56:00 -0500 · 9 months ago Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
Wed, 07 Jan 2026 21:33:00 -0500 · 9 months ago Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock
2026-01-07T13:05:22.000Z · 9 months ago Bright Minds Biosciences, Praxis Precision Medicines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Tue, 06 Jan 2026 16:00:00 -0500 · 9 months ago Bright Minds Biosciences Announces Launch of US$100 Million Public Offering
Tue, 06 Jan 2026 11:52:33 -0500 · 9 months ago New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday
2026-01-06T15:07:53.000Z · 9 months ago Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday
2026-01-06T12:25:21.000Z · 9 months ago Bright Minds announces results from Phase 2 BREAKTHROUGH trial of BMB-101
Tue, 06 Jan 2026 07:16:00 -0500 · 9 months ago Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)
Mon, 05 Jan 2026 16:30:00 -0500 · 9 months ago Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026
Tue, 25 Nov 2025 16:30:00 -0500 · 11 months ago Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting
Mon, 17 Nov 2025 17:29:36 -0500 · 11 months ago Why Bright Minds Biosciences Stock Topped the Market on Monday
Mon, 17 Nov 2025 06:50:00 -0500 · 11 months ago Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)
Thu, 06 Nov 2025 06:30:00 -0500 · 11 months ago Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH
Tue, 20 May 2025 08:00:00 -0400 · 1 year ago Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025
Mon, 28 Apr 2025 08:00:00 -0400 · 1 year ago Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study
Tue, 07 Jan 2025 06:50:00 -0500 · 1 year ago Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
Wed, 13 Nov 2024 12:59:00 -0500 · 1 year ago Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month
Mon, 04 Nov 2024 14:41:00 -0500 · 1 year ago Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
Mon, 28 Oct 2024 08:21:00 -0400 · 1 year ago PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
Mon, 21 Oct 2024 08:30:00 -0400 · 2 years ago Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
Fri, 18 Oct 2024 06:50:00 -0400 · 2 years ago Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
Wed, 16 Oct 2024 10:45:00 -0400 · 2 years ago Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
Oct 3, 2024, 9:00 AM EDT · 2 years ago Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
Sep 19, 2024, 10:00 AM EDT · 2 years ago Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
Sep 12, 2024, 8:00 AM EDT · 2 years ago Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy
Aug 8, 2023, 6:50 AM EDT · 3 years ago Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Jul 20, 2023, 6:50 AM EDT · 3 years ago Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Jul 12, 2023, 10:33 AM EDT · 3 years ago CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)
Apr 19, 2023, 6:50 AM EDT · 3 years ago Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202
Apr 10, 2023, 6:50 AM EDT · 3 years ago Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research
Feb 27, 2023, 6:50 AM EST · 3 years ago Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
Feb 17, 2023, 6:50 AM EST · 3 years ago Bright Minds Biosciences Announces Non-Executive Director Appointment
Feb 8, 2023, 4:05 PM EST · 3 years ago Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements
Jan 27, 2023, 4:05 PM EST · 3 years ago Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Jan 9, 2023, 4:05 PM EST · 3 years ago Bright Minds Biosciences Announces Resignation of Board Member
Dec 2, 2022, 7:07 PM EST · 3 years ago Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement
Nov 28, 2022, 6:50 AM EST · 3 years ago Bright Minds Biosciences Announces Non-Brokered Private Placement
Nov 23, 2022, 11:35 AM EST · 3 years ago Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D.
Sep 7, 2022, 6:50 AM EDT · 4 years ago Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors
Aug 31, 2022, 6:50 AM EDT · 4 years ago Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome
Aug 30, 2022, 3:35 PM EDT · 4 years ago Bright Minds Biosciences Announces Closing of $4 Million Unit Offering
Aug 23, 2022, 9:07 PM EDT · 4 years ago Bright Minds Announces Pricing of Overnight Marketed Offering of Units
Jun 27, 2022, 6:50 AM EDT · 4 years ago Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization
May 12, 2022, 6:50 AM EDT · 4 years ago Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome
May 2, 2022, 6:50 AM EDT · 4 years ago Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties
Apr 19, 2022, 6:50 AM EDT · 4 years ago Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders